Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 820-823

  Morgan, Gareth ^a   Palumbo, Antonio ^b   Dhanasiri, Sujith ^c   Lee, Dawn ^d   Weisel, Katja ^e   Facon, Thierry ^f   Delforge, Michel ^g   Oriol, Albert ^h   Zaki, Mohamed ⁱ   Yu, Xin ⁱ   Sternas, Lars ⁱ   Jacques, Christian ⁱ   Akehurst, Ron ^d,j   Offner, Fritz ^k   Dimopoulos, Meletios A ^l  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c Celgene Ltd   (United Kingdom)

^d BRESMED   (United Kingdom)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f Service des Maladies du Sang   (France)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ CELGENE CORPORATION   (United States)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

Bias; Crossover; Multiple myeloma; Pomalidomide; Survival

Indexed keywords

DEXAMETHASONE; POMALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSED AND REFRACTORY MULTIPLE MYELOMA; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TWO STAGE WEIBULL METHOD; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; KAPLAN MEIER METHOD; MALE; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SALVAGE THERAPY; STATISTICAL BIAS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIAS (EPIDEMIOLOGY); CROSS-OVER STUDIES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE;

EID: 84924034402     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13227     Document Type: Article

References (12)

1. Bird, J.M., Owen, R.G., D'Sa, S., Snowden, J.A., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E., Behrens, J., Jenner, M., Pratt, G., Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) & UK Myeloma Forum. (2014) Guidelines for the diagnosis and management of multiple myeloma 2014. Available: http://www.bcshguidelines.com/documents/MYELOMA_GUIDELINE_Feb_2014_for_BCSH.pdf. Accessed 18 July 2014.
2. Davies, A., Briggs, A., Schneider, J., Levy, A., Ebeid, O., Wagner, S., Kotapati, S. & Ramsey, S. (2012) The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Research in Medicine, 3, e25-e36.
3. Gooding, S., Lau, I.-J., Sheikh, M., Roberts, P., Wong, J., Dickens, E., Elvidge, J., Lee, D. & Ramasamy, K. (2013) Double refractory myeloma: analysis of clinical outcomes and medical-resource utilisation in a single centre. Blood (ASH Annual Meeting Abstracts), 122, 1727.
4. Ishak, K.J., Caro, J.J., Drayson, M.T., Dimopoulos, M., Weber, D., Augustson, B., Child, J.A., Knight, R., Iqbal, G., Dunn, J., Shearer, A. & Morgan, G. (2011) Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value in Health, 14, 672-678.
5. Kumar, S.K., Therneau, T.M., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Witzig, T.E., Lust, J.A., Larson, D.R., Kyle, R.A. & Greipp, P.R. (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clinic Proceedings, 79, 867-874.
6. Kumar, S.K., Lee, J.H., Lahuerta, J.J., Morgan, G., Richardson, P.G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., LeLeu, X., Hulin, C., Klein, S.K., Sonneveld, P., Siegel, D., Bladé, J., Goldschmidt, H., Jagannath, S., Miguel, J.S., Orlowski, R., Palumbo, A., Sezer, O., Rajkumar, S.V., Durie, B.G. & International Myeloma Working Group (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia, 26, 149-157.
7. Latimer, N.R., Abrams, K.R., Lambert, P.C., Crowther, M.J., Wailoo, A.J., Morden, J.P., Akehurst, R.L. & Campbell, M.J. (2013) Adjusting survival time estimates to account for treatment switching in randomised controlled trials - a simulation study. HEDS Discussion Paper 13/06 (Unpublished). Available: http://eprints.whiterose.ac.uk/75249/1/HEDSDP1306.pdf. Accessed 18 July 2014.
8. Morden, J.P., Lambert, P.C., Latimer, N., Abrams, K.R. & Wailoo, A.J. (2011) Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Medical Research Methodology, 11, 4.
9. Morgan, G.J., San Miguel, J., Dhanasiri, S., Lee, D., Palumbo, A., Facon, T., Zaki, M.H., Yu, X., Sternas, L.A., Jacques, C., Weisel, K.C., Offner, F. & Dimopoulos, M.A. (2014) Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): overall survival (OS) results of MM-003 after adjustment for crossover. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 32, 8593.
10. San Miguel, J., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M. (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 14, 1055-1066.
11. Tarant, J.L., Ashcroft, J., Feyler, S., Owen, R.G., Parrish, C. & Cook, G. (2013) Treatment patterns & survival in multiple myeloma patients sequentially exposed to thalidomide, bortezomib & lenalidomide in a UK single centre. Blood (ASH Annual Meeting Abstracts), 122, 5380.
12. Watkins, C., Huang, X., Latimer, N., Tang, Y. & Wright, E.J. (2013) Adjusting overall survival for treatment switches: commonly used methods and practical application. Pharmaceutical Statistics, 12, 348-357.